Bio-Rad Laboratories, Inc. (BIO)
Market Cap | 7.64B |
Revenue (ttm) | 2.61B |
Net Income (ttm) | -322.37M |
Shares Out | 28.55M |
EPS (ttm) | -10.69 |
PE Ratio | n/a |
Forward PE | 25.12 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 300,249 |
Open | 263.50 |
Previous Close | 263.97 |
Day's Range | 262.12 - 270.34 |
52-Week Range | 261.59 - 431.79 |
Beta | 0.95 |
Analysts | Buy |
Price Target | 410.00 (+53.24%) |
Earnings Date | Aug 1, 2024 |
About BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety mar... [Read more]
Financial Performance
In 2023, BIO's revenue was $2.67 billion, a decrease of -4.67% compared to the previous year's $2.80 billion. Losses were -$637.32 million, -82.43% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is $410.0, which is an increase of 53.24% from the latest price.
News
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt ...
Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executiv...
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.
Bio-Rad Reports First-Quarter 2024 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operatin...
Bio-Rad Announces Life Science Group Management Changes
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James ...
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad's Chief Operating Officer Andrew Last to Retire
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, E...
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju ...
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's mana...
Bio Rad Labs rises after posting upbeat fourth-quarter profit
Bio Rad Laboratories reported fourth-quarter profit that beat Wall Street estimates on Thursday, helped by a better-than-expected demand for its diagnostic instruments and quality control products off...
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for th...
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 42nd Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced that Norman Schwartz, Pr...
Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending
Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's shares down...
Bio-Rad Reports Third-Quarter 2023 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for th...
Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for th...
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 2023 Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company's manage...
Bio-Rad Reports Second-Quarter 2023 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the...
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
HERCULES, Calif., & VENLO, the Netherlands--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the compa...
Bio-Rad Announces New Share Repurchase Program
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directo...
Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the...
Bio-Rad Publishes Corporate Sustainability Report for 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its corporate sustainabili...